LJN Newsletters

Analysis of key rulings.

A look at several rulings.

How often do we hear that "everybody sues" in the United States, and that there are "jackpot juries" handing out huge sums of money to undeserving plaintiffs? Is the media to blame for these skewed beliefs or is the media accurate in its portrayal of the tort system, especially the medical malpractice system?

There have been a spate of reports the last few months on alternative fee agreements, or AFAs as they are also known. Subsequently these have stirred a tremendous amount of conversation in the industry.

I-9 enforcement actions have become a lucrative and successful form of agency action and therefore are not likely to subside. Employers should take this hidden area of liability and turn it into a strength through concerted attention and the skillful implementation of measures like those described in this article.

The year 2012 was another banner year for Department of Justice (DOJ) officials charged with prosecuting corporate enforcement actions. The DOJ recovered $4.9 billion from False Claims Act cases, the most ever in a single year.

Dealmakers and their legal advisers have an important choice to make when structuring a controlling stockholder-led buyout.

What a recent Supreme Court decision does is to effectively immunize pharmaceutical generics manufacturers from state tort liability when they use FDA-approved labels for their products deemed equivalent to brand-name FDA-approved drugs.